Metabolism of asymmetric dimethylarginine and its clinical significance;Asimetrik dimetilarjininin metabolizması ve klinik önemi

Turkish Journal of Biochemistry

Volumn 37, Issue 1, 2012, Pages 99-105

  Kemal Erbil, M ^a   Kurt, Yasemin Gülcan ^a   Yaman, Halil ^a   Çakir, Erdinç ^a   Ozgur Akgul E ^a   Çayci, Tuncer ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase; Endothelial dysfunction; Nitric oxide

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; ENDOMETRIOSIS; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; PATHOGENESIS; REVIEW; SCHIZOPHRENIA;

EID: 84859466201     PISSN: None     EISSN: 1303829X     Source Type: Journal    
DOI: 10.5505/tjb.2012.76486     Document Type: Review

References (63)

1. Böger RH, Vallance P, Cooke JP. (2003) Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atherosclerosis Supplements 4: 1-3.
2. Cooke J, Dzau V. (1997) Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular disease. Circulation 96: 379-382.
3. Napoli C, Ignarro LJ. (2001) Nitric oxide and atherosclerosis. Nitric Oxide 5: 88-97
4. Cooke JP ve Losordo DW. (2002) Nitric Oxide and angiogenesis. Circulation 105 (18):2133-5
5. Cooke JP, Tsao PS. (1994) Is NO an endogenous anti atherogenic molecule? Arterioscler. Thromb. Vasc. Biol. 14: 653-5
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. (1992) Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20 (Suppl. 12):S60-62
7. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. (1990) Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol.101:746-52
8. Ogawa T, Kimoto M, Sasaoka K. (1989) Purification and properties of a new enzyme: NG, NG-dimethylarginine dimethylaminohydrolase from rat kidney. J Biol Chem.264:10205-10209
9. Vallance P, Leone A, Calver A, Collier J, Moncada S. (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-75.
10. Clarke S. (1993) Protein methylation. Curr Opin Cell Biol. 5: 977-983
11. Vallance P, Leiper J. (2004) Cardiovascular Biology of the Asymmetric Dimethylarginine: Dimethylarginine Dimethylaminohydrolase Pathway. Arterioscler. Thromb. Vasc. Biol. 24:1023-30
12. Tran CTL, Leiper J M., Vallance P. (2003) The DDAH/ ADMA/NOS pathway. Atherosclerosis Supplements 4:33-40
13. Holven KB, Haugstad TS, Holm T, Aukrust P et al. (2003) Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr. 89: 359-63
14. Teerlink T. (2005) ADMA metabolism and clearance. Vascular Medicine.10:S73-81
15. Leiper J, MacAllister R, Whitley G, Santa Maria J, Chubb A et al. (1999) Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology to microbial arginine deiminases. Biochem J. 343:209-214
16. Kang ES., Cates TB., Harper DN., Chiang TM, Myers LK et al. (2001) An Enzyme Hydrolyzing Methylated Inhibitors of Nitric Oxide Synthase is Present in Circulating Human Red Blood Cells. Free Radical Research, 35: 693-707
17. Murray-Rust J, Leiper J, McAlister M, Tilley S, Santa Maria J et al. (2001) Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol. 8:679-683
18. Leiper J, Murray-Rust J, McDonald N, Vallance P. (2002) S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 99: 13527-13532
19. Knipp M, Charnock JM, Garner CD, Vasak M. (2001) Structural and functional characterization of the Zn (II) site in dimethylargininase-1 (DDAH-1) from bovine brain. Zn (II) release activates DDAH-1. J Biol Chem. 276:40449-40456
20. Forbes SP, Druhan LJ, Guzman JE, Parinandi N, Zhang L et al. (2008) Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation. Biochemistry 47 (6):1819-26.
21. Pope AJ, Karuppiah K, Cardounel AJ. (2009) Role of the PRMTDDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res. 60 (6):461-5.
22. Reade MC, Clark MF, Young JD, Boyd CA. (2002) Increased cationic amino acid flux through a newly expressed transporter in cells overproducing nitric oxide from patients with septic shock. Clin Sci.102:645-50
23. Mendes Ribeiro AC, Brunini TM, Ellory JC, Mann GE. (2001) Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc Res. 49:697-712
24. Kaye DM, Ahlers BA, Autelitano DJ, Chin-Dusting JP. (2000) In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 102:2707-12
25. Wu G, Morris SM Jr. (1998) Arginine metabolism: nitric oxide and beyond. Biochem J 336:1-17
26. Wilcken D.E.L., Sim A.S., Wang J., Wang X.L. (2007) Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Molecular Genetics and Metabolism 91:309-317
27. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23:1455-59
28. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, et al. (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation;109:172-177
29. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto FA, Tripepi G et al. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-17
30. Siroen MP, Warlé MC, Teerlink T, Nijveldt RJ, Kuipers EJ et al. (2004) The transplanted liver graft is capable of clearing asymmetric dimethylarginine. Liver Transpl;10:1524-30
31. Nijveldt RJ, Teerlink T, van der Hoven B, Siroen MPC, Kuik DJ et al. (2003) Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr;22:23-30
32. Nijveldt RJ, Teerlink T, van Leeuwen PA. (2003) The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr;22:99-104
33. Fickling SA, Holden DP, Cartwright JE, Nussey SS, Vallance P et al. (1999) Regulation of macrophage nitric oxide synthesis by endothelial cells: a role NG, NG dimethylarginine. Acta Physiol Scand.;167:145-150
34. Lu T.M., Ding Y.A., Lin S.J., Lee W.S. and Tai H.C., (2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J, 24, pp. 1912-1919
35. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ et al. (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res, 97, e53-e59
36. Meinitzer A, Seelhorst U., Wellnitz B., Halwachs-Baumann G., Boehm B.O. et al. (2007) Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem Feb;53 (2):273-83.
37. Tanaka M, Sydow K, Gunawan F, Jacobi J, Tsao PSet al. (2005) Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation;112 (11):1549-1556.
38. Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J et al. (2007) Isoform-specific regulation by N (G), N (G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/ NO. Circ Res;101 (6):627-635
39. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M et al. (2007) Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med;13 (2):198-203
40. Jacobi J, Tsao P. (2008) Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol;28:224-37
41. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A et al. (2005) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis;47:42-50
42. Zoccali C, Benedetto FA, Maas R, Mallamaci F. Tripepi G. et al. (2002) Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol.;13:490-96
43. Ravani P, Tripepi G, Malberti F, Testa S. Mallamaci F et al. (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 16:2449-55
44. Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T et al. (2005) Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation. Dec 27;80 (12):1660-6.
45. Nijveldt RJ, Teerlink T, van der Hoven B, Siroen MP, Kuik DJ et al. (2003) Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr;22:23-30
46. Das UN, Repossi G, Dain A, Eynard AR. (2011) L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes. Front Biosci. Jan 1;16:13-20.
47. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. (2002) Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J; 66: 811-815.,
48. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. (2002) Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N (G), N (G)-dimethylarginine in human essential hypertension. Am J Hypertens; 15: 590-593
49. Yilmaz MI, Saglam M, Sonmez A, Caglar K, Cakir E. (2007) Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif.;25 (4):327-35.
50. Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ et al. (2008) ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J. Am. Soc. Nephrol.;19 (2):388-95
51. Cayci T, Akgul EO, Gulcan Kurt Y, Ceyhan TS, Aydin I et al. (2011) The levels of nitric oxide and asymmetric dimethylarginine in the rat endometriosis model., J Obstet Gynaecol Res. (ISI), Apr 12, DOI: 10.1111/j.1447-0756. (2010).01482.x.
52. Cakir E, Ozcan O, Yaman H, Akgul EO, Bilgi C et al. (2005) Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients. The Journal of Clinical Endocrinology & Metabolism.; 90 (3):1651-4.
53. Celik C, Cayci T, Ozdemir B, Akgul EO, Zincir S et al. (2011) Plasma asymmetric dimethylarginine (ADMA) concentrations in patients with first and multiple episode schizophrenia. Psychiatry Res. Aug 11. [Epub ahead of print]
54. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S et al. (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation; 99 (9):1141-46.
55. Böger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation (1998); 98:1842-47.
56. Sahin M, Arslan C, Naziroglu M, Tunc SE, Demirci M et al. (2006) Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. Ann Clin Lab Sci.;36 (4):449-54
57. Hermenegildo C, Medina P, Peiro M, Segarra G, Vila JM et al. (2002) Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab;87:5636-40
58. Rawal N, Lee YJ, Whitaker JN, Park JO, Paik WK et al. (1995) Urinary excretion of NG dimethylarginines in multiple sclerosis patients: preliminary observations. J Neurol Sci 129:186-91
59. Schnog JB, Teerlink T, van der Dijs FP, Duits AJ, Muskiet FA; (2005) CURAMA Study Group. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol; 84:282-286
60. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J. et al. (2004) Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med; 42:1377-83
61. Valtonen P, Karppi J, Nyysson K, Valkonen VP, Halonen T et al. (2005) Comparison of
62. HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chrom B;828:97-102
63. Martens-Lobenhoffer J, Westphal S, Awiszus F, Bode-Boger SM, Luley C. (2005) Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA? Clin Chem;51:2188-9